LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Serum Cortisol Predicts Death and Critical Disease

By LabMedica International staff writers
Posted on 12 Dec 2012
Print article
Several biomarkers and prognostic scores have been evaluated to predict prognosis in community-acquired pneumonia (CAP).

Serum cortisol concentration is associated with severity and mortality and predicts persistent clinical instability, making it a potential parameter to improve the identification of patients with high risk for a complicated disease course.

Scientists at the University Hospital Carl Gustav Carus (Dresden, Germany) studied 984 hospitalized CAP-patients and measured their serum cortisol concentrations and compared its prognostic accuracy to the leucocyte count, C-reactive protein levels, and the clinical prediction CRB-65 score. Serum cortisol was analyzed by a chemiluminescence immunoassay (Roche Diagnostics; Mannheim, Germany). This assay has a measurement range of 0.5 to 1,750 nmol/L; higher concentrations were analyzed by dilution of the serum sample.

Serum cortisol levels on admission were significantly higher in nonsurvivors at a median of 870 nmol/L when compared to survivors at 602 nmol/L. In patients with critical pneumonia the median was 972 nmol/L compared with a median 598 nmol/L in patients with noncritical pneumonia. In subgroup analyses, cortisol independently predicted critical pneumonia when compared to procalcitonin levels.

A causative microbiological pathogen was detected in 195 patients (20%). Of these, typical bacteria were found in 84 patients (43%), atypical bacteria in 64 (33%), viruses in 29 (15%) and mixed infection in 18 (9%). Streptococcus pneumoniae was the most frequently isolated pathogen and was found in 71 patients (36%).

The authors concluded that cortisol predicts mortality and critical disease in hospitalized CAP-patients independently of clinical scores and inflammatory biomarkers. They recommend that it should be incorporated into trials assessing optimal combinations of clinical criteria and biomarkers to improve initial high-risk prediction in CAP. The study was originally published in April 2012 in the Biomedical Central Journal BMC Infectious Diseases.

Related Links:

University Hospital Carl Gustav Carus
Roche Diagnostics



Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.